DRI Healthcare Trust (TSE:DHT.UN) Receives C$17.94 Average Target Price from Analysts

Shares of DRI Healthcare Trust (TSE:DHT.UN) have been given an average recommendation of “Moderate Buy” by the six brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is C$17.94.

A number of research analysts recently commented on DHT.UN shares. Raymond James decreased their price target on shares of DRI Healthcare Trust from C$23.00 to C$22.00 in a research note on Wednesday, November 13th. CIBC lowered their target price on DRI Healthcare Trust from C$19.50 to C$18.00 and set an “outperform” rating on the stock in a research note on Thursday, December 12th. Finally, Scotiabank boosted their price target on DRI Healthcare Trust from C$21.00 to C$22.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th.

DRI Healthcare Trust Price Performance

DHT.UN stock opened at C$12.33 on Friday. The business’s 50 day simple moving average is C$12.23 and its 200 day simple moving average is C$12.57. DRI Healthcare Trust has a 1-year low of C$10.39 and a 1-year high of C$17.43.

About DRI Healthcare Trust

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term.